USP30 Inhibitors for Parkinson's Disease

USP30 Inhibitors for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">USP30 Inhibitors for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">Mitochondrial targeting sequence (MTS)</td>
<td>1-30</td>
</tr>
<tr>
<td class="label">USP catalytic domain</td>
<td>120-480</td>
</tr>
<tr>
<td class="label">C-terminal region</td>
<td>480-517</td>
</tr>
<tr>
<td class="label">Therapeutic Effect</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Enhanced ubiquitination</td>
<td>Preservation of ubiquitin on OMM proteins</td>
</tr>
<tr>
<td class="label">Increased receptor recruitment</td>
<td>p62, OPTN, NDP52 more efficiently recruited</td>
</tr>
<tr>
<td class="label">Improved mitophagy</td>
<td>More efficient clearance of damaged mitochondria</td>
</tr>
<tr>
<td class="label">Neuronal protection</td>
<td>Reduced oxidative stress and apoptosis</td>
</tr>
<tr>
<td class="label">Alpha-synuclein reduction</td>
<td>Improved mitophagy decreases aggregation[@wang2023]</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Denali Therapeutics</td>
<td>DNL309</td>
</tr>
<tr>
<td class="label">DepYmed</td>
<td>TH3289</td>
</tr>
<tr>
<td class="label">Bristol Myers Squibb</td>
<td>BMS-986467</td>
</tr>

USP30 Inhibitors for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">USP30 Inhibitors for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">Mitochondrial targeting sequence (MTS)</td>
<td>1-30</td>
</tr>
<tr>
<td class="label">USP catalytic domain</td>
<td>120-480</td>
</tr>
<tr>
<td class="label">C-terminal region</td>
<td>480-517</td>
</tr>
<tr>
<td class="label">Therapeutic Effect</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Enhanced ubiquitination</td>
<td>Preservation of ubiquitin on OMM proteins</td>
</tr>
<tr>
<td class="label">Increased receptor recruitment</td>
<td>p62, OPTN, NDP52 more efficiently recruited</td>
</tr>
<tr>
<td class="label">Improved mitophagy</td>
<td>More efficient clearance of damaged mitochondria</td>
</tr>
<tr>
<td class="label">Neuronal protection</td>
<td>Reduced oxidative stress and apoptosis</td>
</tr>
<tr>
<td class="label">Alpha-synuclein reduction</td>
<td>Improved mitophagy decreases aggregation[@wang2023]</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Denali Therapeutics</td>
<td>DNL309</td>
</tr>
<tr>
<td class="label">DepYmed</td>
<td>TH3289</td>
</tr>
<tr>
<td class="label">Bristol Myers Squibb</td>
<td>BMS-986467</td>
</tr>
<tr>
<td class="label">Roche</td>
<td>Compound 9</td>
</tr>
<tr>
<td class="label">Academic consortia</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Molecular weight</td>
<td><500 Da</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>B/P ratio >1</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>>100x vs other DUBs</td>
</tr>
<tr>
<td class="label">Metabolic stability</td>
<td>CLint <20 μL/min/mg</td>
</tr>
<tr>
<td class="label">Solubility</td>
<td>>10 mg/mL</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Timeline</td>
</tr>
<tr>
<td class="label">Lead identification</td>
<td>2019-2021</td>
</tr>
<tr>
<td class="label">Lead optimization</td>
<td>2021-2023</td>
</tr>
<tr>
<td class="label">IND-enabling studies</td>
<td>2024-2025</td>
</tr>
<tr>
<td class="label">Phase I trials</td>
<td>2026-2027</td>
</tr>
<tr>
<td class="label">Phase II trials</td>
<td>2028-2029</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">Phospho-ubiquitin (pS65-Ub)</td>
<td>Blood/CSF</td>
</tr>
<tr>
<td class="label">Mitophagy flux</td>
<td>Skin fibroblasts</td>
</tr>
<tr>
<td class="label">Mitochondrial DNA copy number</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">USP30 expression</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Active-site inhibitors</td>
<td>Well-validated mechanism</td>
</tr>
<tr>
<td class="label">Allosteric inhibitors</td>
<td>Improved selectivity</td>
</tr>
<tr>
<td class="label">Covalent inhibitors</td>
<td>Extended duration</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">USP30i + LRRK2i</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">USP30i +GBA chaperone</td>
<td>Lysosomal + mitochondrial</td>
</tr>
<tr>
<td class="label">USP30i + anti-α-syn antibody</td>
<td>Target alpha-synuclein</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">USP30</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">PINK1</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Parkin</td>
<td>Gene therapy</td>
</tr>
<tr>
<td class="label">TFEB</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Solution</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Design for high B/P ratio</td>
</tr>
<tr>
<td class="label">Sustained exposure</td>
<td>Optimize PK/PD relationship</td>
</tr>
<tr>
<td class="label">Dosing frequency</td>
<td>Improve half-life</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Solution</td>
</tr>
<tr>
<td class="label">Off-target DUBs</td>
<td>Structure-based design</td>
</tr>
<tr>
<td class="label">Protease off-targets</td>
<td>Broad profiling</td>
</tr>
<tr>
<td class="label">Kinase off-targets</td>
<td>Panel screening</td>
</tr>
</table>

USP30 (Ubiquitin-specific peptidase 30) is a mitochondria-localized deubiquitinase that negatively regulates mitophagy by removing ubiquitin chains from mitochondrial proteins. Inhibition of USP30 promotes mitophagy and mitochondrial quality control, making it a promising therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease)[@bingol2014][@kerr2017].

USP30 is uniquely localized to the outer mitochondrial membrane (OMM), where it acts as a "brake" on the PINK1-Parkin mitophagy pathway. By removing ubiquitin from mitochondrial proteins that have been tagged for degradation, USP30 prevents the selective autophagy of damaged mitochondria. In PD, where mitochondrial dysfunction is a central pathogenic mechanism, inhibiting USP30 can enhance the clearance of dysfunctional mitochondria and protect dopaminergic neurons[@kluge2018][@bose2018].

Scientific Rationale

USP30 Biology

USP30 is a 517-amino acid deubiquitinase localized to the outer mitochondrial membrane with distinctive structural features:

The enzyme specifically removes ubiquitin from mitochondrial proteins, counteracting the [PINK1](/genes/pink1)-[PARKIN](/genes/parkin) mitophagy pathway. When PINK1 accumulates on damaged mitochondria, it phosphorylates ubiquitin and Parkin, triggering mitophagy. USP30 reverses this process by removing the ubiquitin chains that mark mitochondria for degradation[@yoshida2019][@marcassa2018].

Role in Parkinson's Disease

Loss-of-function mutations in [PINK1](/genes/pink1) and [PARKIN](/genes/parkin) cause early-onset familial Parkinson's disease. Even in sporadic PD, mitophagy is impaired. By inhibiting USP30:

Genetic Evidence

Recent studies have identified USP30 variants associated with PD risk[@li2022]:

• Loss-of-function variants: Associated with increased PD risk
• Protective variants: Associated with reduced PD risk
• GWAS signals in the USP30 locus identified in Japanese and European populations
• USP30 expression is elevated in PD patient brains[@iwaki2025]

USP30 and Alpha-Synuclein

Beyond mitophagy, USP30 influences alpha-synuclein pathology through mitochondrial quality control pathways:

• Mitochondrial dysfunction promotes alpha-synuclein aggregation
• Enhanced mitophagy reduces intracellular alpha-synuclein accumulation
• OPTN/TBK1 pathway links USP30 to alpha-synuclein clearance[@wang2023][@ordonez2024]

Drug Development

Current Programs

Several pharmaceutical companies have active USP30 inhibitor programs:

Mechanism of Action

USP30 inhibitors work through:

The compounds are designed to cross the blood-brain barrier and achieve sufficient brain concentrations for efficacy["@fitzgerald2024"].

Chemical Properties

Preclinical Data

In animal models, USP30 inhibition demonstrates[@phd2020][@castle2023][@ordonez2024]:

• Enhanced mitophagy in dopaminergic neurons
• Reduced alpha-synuclein pathology
• Protected substantia nigra neurons
• Improved motor performance
• No significant toxicity

Clinical Pipeline

Development Timeline

As of 2026, no USP30 inhibitors have reached clinical trials for PD. However:

IND-Enabling Programs

Denali's DNL309 and DepYmed's TH3289 are in late preclinical development with[@denali2025][@depymed2024]:

• GLP toxicology studies ongoing
• Formulation development for oral delivery
• Biomarker assays for target engagement
• Patient selection strategies being evaluated

Biomarker Development

Critical biomarkers for clinical development:

Therapeutic Approaches

Small Molecule Inhibitors

The primary approach being pursued:

Alternative Approaches

Gene Therapy

AAV-mediated USP30 knockdown offers an alternative[@castle2023]:

• Long-lasting expression in neurons
• Single administration potential
• Viral delivery challenges for CNS
• Not easily reversible

Combination Strategies

Comparison with Other Mitophagy-Targeted Approaches

Safety Considerations

Mechanism-Based Toxicity

Potential risks from excessive mitophagy:

• Excessive mitochondrial clearance affecting energy metabolism
• Disruption of mitochondrial dynamics (fusion/fission balance)
• Off-target effects on other cellular processes

Preclinical Safety Findings

To date, USP30 inhibition shows[@toensing2023]:

• Wide therapeutic window in animal models
• No major organ toxicity at efficacious doses
• Reversible effects on discontinuation
• No developmental toxicity in initial studies

Challenges and Solutions

Delivery Challenges

Selectivity Challenges

Future Directions

Research Priorities

Unanswered Questions

• Optimal dosing regimen: Intermittent vs. continuous
• Biomarker correlates: Which markers predict efficacy
• Patient selection: Which PD subtypes will benefit most
• Combination approaches: Optimal partner mechanisms

Cross-Linking to Related Pages

• [USP30 Gene](/genes/usp30) — Gene information and biology
• [PINK1/Parkin Pathway](/mechanisms/pink1-parkin-mitophagy-pathway) — Mitophagy mechanism
• [Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control) — Broader context
• [Mitophagy in Neurodegeneration](/mechanisms/mitophagy-pathway-neurodegeneration) — Disease relevance
• [Parkinson's Disease](/diseases/parkinsons-disease) — Target disease

Market and Development Landscape

The USP30 inhibitor field has grown significantly[@bmj2025]:

• 5+ companies with active programs
• $500M+ invested in discovery and development
• Multiple IND applications expected 2026-2027
• Growing interest from larger pharma companies

Conclusion

USP30 inhibitors represent one of the most promising approaches to enhance mitophagy in Parkinson's disease. By removing the "brake" on the PINK1-Parkin pathway, these compounds can promote the clearance of damaged mitochondria that accumulate in dopaminergic neurons. The strong genetic evidence linking USP30 to PD risk, combined with compelling preclinical data, has driven significant pharmaceutical investment in this target.

While no USP30 inhibitors have reached clinical trials yet, multiple programs are in late preclinical development with IND filings expected soon. Success in the clinic would represent a major advance in disease-modifying treatment for Parkinson's disease.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
• [The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB